These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 18094073)

  • 1. Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.
    Goncharova EA; Goncharov DA; Chisolm A; Spaits MS; Lim PN; Cesarone G; Khavin I; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
    Mol Pharmacol; 2008 Mar; 73(3):778-88. PubMed ID: 18094073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signal transducer and activator of transcription 3 is required for abnormal proliferation and survival of TSC2-deficient cells: relevance to pulmonary lymphangioleiomyomatosis.
    Goncharova EA; Goncharov DA; Damera G; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
    Mol Pharmacol; 2009 Oct; 76(4):766-77. PubMed ID: 19596836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: Role for tumor suppressor TSC2.
    Goncharova EA; Goncharov DA; Spaits M; Noonan DJ; Talovskaya E; Eszterhas A; Krymskaya VP
    Am J Respir Cell Mol Biol; 2006 May; 34(5):561-72. PubMed ID: 16424383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.
    Atochina-Vasserman EN; Goncharov DA; Volgina AV; Milavec M; James ML; Krymskaya VP
    Am J Respir Cell Mol Biol; 2013 Nov; 49(5):704-9. PubMed ID: 23947572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM).
    Goncharova EA; Goncharov DA; Eszterhas A; Hunter DS; Glassberg MK; Yeung RS; Walker CL; Noonan D; Kwiatkowski DJ; Chou MM; Panettieri RA; Krymskaya VP
    J Biol Chem; 2002 Aug; 277(34):30958-67. PubMed ID: 12045200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of beta-agonists on LAM progression and treatment.
    Le K; Steagall WK; Stylianou M; Pacheco-Rodriguez G; Darling TN; Vaughan M; Moss J
    Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E944-E953. PubMed ID: 29339522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.
    Makovski V; Haklai R; Kloog Y
    Int J Cancer; 2012 Mar; 130(6):1420-9. PubMed ID: 21500191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
    Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
    J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
    Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
    PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequent [corrected] hyperphosphorylation of ribosomal protein S6 [corrected] in lymphangioleiomyomatosis-associated angiomyolipomas.
    Robb VA; Astrinidis A; Henske EP
    Mod Pathol; 2006 Jun; 19(6):839-46. PubMed ID: 16575396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis.
    Krymskaya VP
    Proc Am Thorac Soc; 2008 Jan; 5(1):119-26. PubMed ID: 18094094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model.
    Prizant H; Taya M; Lerman I; Light A; Sen A; Mitra S; Foster TH; Hammes SR
    Endocr Relat Cancer; 2016 Apr; 23(4):265-80. PubMed ID: 26880751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TSC2 modulates cell adhesion and migration via integrin-α1β1.
    Moir LM; Black JL; Krymskaya VP
    Am J Physiol Lung Cell Mol Physiol; 2012 Oct; 303(8):L703-10. PubMed ID: 22923640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTORC2 is required for proliferation and survival of TSC2-null cells.
    Goncharova EA; Goncharov DA; Li H; Pimtong W; Lu S; Khavin I; Krymskaya VP
    Mol Cell Biol; 2011 Jun; 31(12):2484-98. PubMed ID: 21482669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor.
    Evans JF; Rue RW; Mukhitov AR; Obraztsova K; Smith CJ; Krymskaya VP
    Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31878201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway.
    Makovski V; Jacob-Hirsch J; Gefen-Dor C; Shai B; Ehrlich M; Rechavi G; Kloog Y
    Cell Death Dis; 2014 Dec; 5(12):e1557. PubMed ID: 25476905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells.
    Lee PS; Tsang SW; Moses MA; Trayes-Gibson Z; Hsiao LL; Jensen R; Squillace R; Kwiatkowski DJ
    Am J Respir Cell Mol Biol; 2010 Feb; 42(2):227-34. PubMed ID: 19395678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic effects of urotensin-II in cells lacking tuberous sclerosis complex-2.
    Goldberg AA; Joung KB; Mansuri A; Kang Y; Echavarria R; Nikolajev L; Sun Y; Yu JJ; Laporte SA; Schwertani A; Kristof AS
    Oncotarget; 2016 Sep; 7(38):61152-61165. PubMed ID: 27458154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis.
    Atochina-Vasserman EN; Abramova E; James ML; Rue R; Liu AY; Ersumo NT; Guo CJ; Gow AJ; Krymskaya VP
    Am J Physiol Lung Cell Mol Physiol; 2015 Dec; 309(12):L1447-54. PubMed ID: 26432869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predisposition to tetraploidy in pulmonary vascular smooth muscle cells derived from the Eker rats.
    Gui Y; He GH; Walsh MP; Zheng XL
    Am J Physiol Lung Cell Mol Physiol; 2007 Sep; 293(3):L702-11. PubMed ID: 17575014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.